Cases & Deals

Medicxi Ventures participates in €3.3 million investment in Yukin Therapeutics

Clients Medicxi Ventures (UK) LLP

Jones Day represented Medicxi Ventures (UK) LLP in connection with its €3.3 million (US$3.7 million) investment in Yukin Therapeutics, a French-based company engaged in the research and development of small molecules targeting the kinase NIK for the treatment of cancer and inflammatory diseases.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.